Enterprise Therapeutics Raises $41 Million Series B Funding To Develop Muco-Regulatory Pipeline

Raises Series B round co-led by Versant Ventures and Novartis Venture Fund, with Forbion, Epidarex and IP Group completing the syndicate

Funding will advance pipeline of novel treatments for respiratory diseases (cystic fibrosis, chronic obstructive pulmonary disease and asthma) into clinical development, including Phase 2 proof of concept